Overview

Study to Evaluate SAGE-324 in Participants With Essential Tremors

Status:
Not yet recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the dose-response relationship of different doses of SAGE-324 on upper extremity tremor in participants with essential tremors (ET).
Phase:
Phase 2
Details
Lead Sponsor:
Sage Therapeutics
Collaborator:
Biogen